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The tracks of the train point where it is going—they also reveal where it has been. The tracks of the leopard in 
the snow do only the latter. Which is the case for epigenetic 
processes in cardiovascular health and disease? Chromatin 
enables bespoke storage and retrieval of genetic informa-
tion across the hundreds of cells in a multicellular organism. 
Chromatin is also perhaps the largest, in terms of physical size 
and list of component parts, and most functionally diverse mo-
lecular structure in existence, enabling the vast diversity of the 
multicellular world. The goals of this essay are (1) to review 
recent advancements in the concepts of epigenomics; (2) to 
summarize the evidence that epigenomic processes partici-
pate in normal and diseased cardiovascular physiology; and 
(3) to stimulate discussion about the prospects for novel basic 
science and translational investigations of epigenomes in the 
cardiovascular system.
In development, the setting in which epigenesis has been 
most extensively examined, the task of epigenetic processes 
is to guide the unidirectional differentiation of cells. In adult-
hood, epigenetic mechanisms provide stability, maintaining 
the blueprints laid down in development and resisting envi-
ronmental stresses and stochastic intracellular changes. In car-
diovascular disease, an area in which epigenetic processes are 
increasingly appreciated to operate and in which insights into 
human health are the most actionable, the task, teleologically, 
of chromatin is not all that clear. Are the epigenetic processes 
at work in the cell during disease always combating the insult, 
attempting to restore and preserve healthy adult phenotypes? 
Have epigenetic processes been hijacked by evolution to 
contribute to cell survival decisions? What are the operational 
principles of epigenetics and how are they distinguished from 
gene regulation? For this essay, we define an epigenome as a 
genome plus everything binding to and modifying it (Glossary 
in the Online Data Supplement).
Evidence has recently accumulated that epigenomic pro-
cesses play a central role in cardiovascular disease, including 
(1) genetic and pharmacological gain- and loss-of-function 
studies in the cardiovascular system targeting individual his-
tone-modifying enzymes, chromatin remodelers, chromatin 
structural components, and regulatory RNAs can induce or 
prevent pathology; (2) descriptive epigenomic investigations 
from humans and animal models demonstrate that widespread 
reprogramming of histone modifications, DNA methylation, 
and protein binding occurs during the development of disease; 
(3) data have arisen that indicate epigenomic processes are 
interconnected with other cellular events (such as metabolism, 
differentiation, and cell death) that are deranged in disease and 
that modulation of these epigenetic processes may hold poten-
tial for therapeutic intervention. Let us now examine recent 
advancements in our understanding of how chromatin controls 
gene expression and consider the implications for cardiovas-
cular disease.
Structural Components of Chromatin and 
Their Regulation in the Cardiovascular System
The epigenome has 2 fundamental components: the structural 
features of chromatin and the enzymes, RNAs, small mol-
ecules, and processes that modify these features. For example, 
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a nucleosome is the chromatin structural unit, but an ATP-
dependent chromatin remodeler is an enzyme complex that 
modifies this structural unit. Here is how you make a nucleo-
some1: bind histone H3 to histone H4 and combine 2 of these 
dimers to form a tetramer; then combine this tetramer with his-
tone H2A and histone H2B, twice, and embrace this octamer 
in turn with ≈145 to 147 bp of DNA. Crystal structures2 of the 
nucleosome in 1997 revealed this octameric protein complex 
to be assembled through histone fold dimers of H2A with H2B 
and H3 with H4. The intervening years have seen the discovery 
of multiple histone isoform variants that can exert structural 
changes at the atomic level on the functional properties of the 
nucleosome: 1 example is histone H2A.z, an H2A variant as-
sociated with active transcription, which operates by altering 
the interfaces between H2A–H2B dimers, as well as among 
the entire tetramer, partially destabilizing the nucleosome core 
(thereby facilitating nucleosome eviction during transcrip-
tion).3 Another example is centromeric histone H3, called 
CENP-A, which replaces H3 in centromeric nucleosomes, 
altering the interactions among histones but maintaining the 
octameric structure.4 Mammalian genomes encode multiple 
versions of core histones, with each family hosting multiple 
variants of unknown significance. These histone isoform vari-
ants have been shown to participate in development and dis-
ease through altered roles in DNA replication, chromosome 
packaging, and DNA accessibility.5,6 Proteomics experiments 
have demonstrated variable expression of these isoforms in dif-
ferent cell types, including in the heart,7 and the stoichiometry 
of histones changes with disease, such as in pressure overload 
hypertrophy.8 In general, however, the nucleosome is among 
the most conserved protein structures known.
Where nucleosomes bind along the genome is influ-
enced—certainly in reconstituted systems but likely also in 
vivo to some degree—by primary DNA sequence, with poly 
dA:dT–rich regions being comparably depleted of nucleo-
somes, due in part to the biophysical properties of these re-
gions that resist bending necessary for nucleosome binding.9 
An additional class of chromatin structural element includes 
non-nucleosome chromatin structural proteins, such as his-
tone H1 family proteins, CTCF (CCCTC-binding factor), 
and HMG (high mobility group) proteins. Histone H1, the so-
called linker histone (also known as histone H5), is not part 
of the nucleosome core particle but may participate in the for-
mation of higher order chromatin fibers through interactions 
with nucleosome histones and DNA.10 Structures of nucleo-
somes with H1 (which has been termed the chromatosome11) 
show the latter nestled just outside of the core,12,13 making 
independent contacts with DNA, but whether linker histones 
are obligatory components of a structural feature in eukaryotic 
chromatin remains a matter of debate. Observations from a 
variety of eukaryotic systems implicate linker histone H1 in 
genomic functions, including DNA repair/stability, replica-
tion, and transcription.14 CTCF and HMG proteins each have 
likewise been attributed a wide range of possible functions, 
based mostly on gain-/loss-of-function studies in cell systems. 
As a general mechanism, CTCF binds DNA and facilitates 
chromatin looping (ie, the formation of semistable long range 
intrachromosomal interactions, spanning kilobases)15; speci-
ficity may arise in different cell types to facilitate regulatory 
interactions. HMG proteins, of which there are many families, 
bind and stabilize distinct structural features in DNA, thereby 
contributing to high order chromatin anatomy and perhaps 
assemblies of nucleosomes. Interestingly, the HMGA fam-
ily of these proteins has been implicated in cardiac disease, 
with both hetero- and homozygous knockout mice developing 
hypertrophy.16
How nucleosomes position along chromatin is largely 
specified, in multicellular eukaryotes, by ATP-dependent 
chromatin remodeling enzymes and the trio of protein classes 
responsible for the so-called the histone code, those being 
writers, erasers, and readers, that add, remove, or interpret his-
tone modifications, respectively. Although all these processes 
exist in other organelles and compartments (indeed many 
purported histone modifiers in fact interface with nonhistone, 
non-nuclear proteins), the allegorical grammar terminology 
adopted for chromatin post-translational modification (PTMs) 
has been particularly helpful in conceptualizing experiments 
into how gene expression is regulated and particularly effec-
tive in biasing the interpretation of results.
Since their discovery and association with transcription 
or its inhibition, histone modifications have been the source 
of innumerable question-begging experiments and seem-
ingly endless rounds of debate on their relationship to gene 
regulation.17–19 Histone post-translational modifications were 
originally described in the 1960s20 but only with the advent of 
chromatin immunoprecipitation and DNA sequencing (ChIP-
seq; Figures 1 and 2) studies could the occupancy of these 
modifications be correlated, in a genome-wide manner in a 
single experiment, with gene transcription. Histone H3 has 
been particularly well characterized and shown to exhibit con-
served regulatory behavior across species and cell type, with 
consensus existing about the roles of H3K27me3 in revers-
ible gene silencing, H3K27ac in gene activation, H3K4me3 in 
gene activation, H3K9me3 in more lasting gene silencing and 
heterochromatin, although other histone isoforms, such as res-
idue K20me on histone H4 (associated with gene silencing), 
exhibit evolutionarily conserved relationships to gene regula-
tion. Histone modifications are associated with a variety of 
processes not related directly to transcription, including rep-
lication, DNA repair, mitosis, and cell division,5,6,22 although 
these processes tend to be better understood in model organ-
isms like yeast and not extensively studied in mammalian sys-
tems in vivo.
The histone code hypothesis (discussed in greater detail 
below), as originally articulated by Strahl and Allis,17 states 
that a prescribed transcriptional or other genomic regulatory 
Nonstandard Abbreviations and Acronyms
ChIP-seq chromatin immunoprecipitation sequencing
DNMT DNA methyltransferase
HDAC histone deacetylase
HMG high mobility group
lncRNA long noncoding RNA
PRC polycomb repressive complex
TAD topologically associated domain
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response arises, or is evoked, from a certain combination of 
histone PTMs in vivo. This hypothesis has tacitly established 
a framework in which to examine large amounts of ChIP-seq 
data, inspecting for regions of correlation between histone 
marks and gene expression. The resolution of most ChIP-seq 
peaks (≈200–1000 bp) is highly dependent on the informatics 
tools used to map reads and subsequently call peaks23 (because 
protein occupancy on the genome makes a much smaller foot-
print, it is consequently often unknown exactly where a protein 
binds; the less commonly applied ChIP-exo24 and X-ChIP-
seq,25 achieving ≈25 to 50 bp resolution, are exceptions). Thus, 
one does not know whether histone PTMs occupy the same nu-
cleosome, which would be required for a histone PTM reader 
protein to distinguish a full, accurate code from a partial and 
inaccurate code (example of partial exception: chromatin di-
gestion to single nucleosomes coupled with mass spectrometry 
proved coexistence of modifications on the same particle [in 
an antibody-independent manner], which incidentally revealed 
that bivalency can occur at the single nucleosome level [ie, dif-
ferent histone H3 copies in the same complex have opposing—
that is one has an active and the other a repressive—PTMs], 
so-called asymmetrically modified nucleosomes26).
Histone writers and erasers are signal transduction process-
es that sometimes use histones as substrates. The concept of the 
reader, however, is an indispensable component of epigenetic 
language and one without obvious counterpart outside the con-
text of the chromatin (scaffolding proteins in signaling networks 
are a similar but distinct concept). To work as advertised—that 
is, to distinguish target region α from nontarget β, to bind α, 
and then to do something—readers must be able to simultane-
ously recognize and discriminate between histone PTMs, which 
has been shown in some model systems,27 but has not been 
demonstrated to operate in mammals in a tissue-specific man-
ner. Progress has recently been made in the area of heart fail-
ure, however, with the example of the BET (bromodomain and 
extra-terminal) bromodomain protein BRD4 (bromodomain-
containing protein 4), whose inhibition with the small molecule 
JQ1 prevents hypertrophy and associated transcriptional chang-
es28,29 and whose pharmacological inhibition reverses some of 
the fibrotic and deleterious structural remodeling in the wake 
of infarction or pressure overload (having no effect on physi-
ological hypertrophy).30 These studies have raised the intrigu-
ing possibility that epigenetic readers may be novel targets of 
epigenetic therapy in cardiovascular disease31 given their cell 
type–specific expression patterns, ability to integrate the actions 
of multiple chromatin modifiers, and their role to program gene 
expression with high fidelity at individual loci.
All 4 core histones are extensively post-translationally 
modified, with different histones (and different modifications) 
studied to varying extents and degrees of rigor and functional 
depth. The bane of accurate and reproducible proteomic mass 
spectrometry is that a truly unbiased experiment to detect 
PTMs will identify many, with no certainty about which ones 
are important versus otiose signaling noise. The most common 
answer to the question of which PTMs are important for chro-
matin regulation is some variation on “only the ones shown 
to be functionally involved in a phenotype.” Often the PTMs 
deemed most tantalizing are those previously published on in 
lower organisms and those for which commercially available 
antibodies exist. In the chromatin world, these PTMs and the 
associated antibodies are the ones getting the most game time 
in ChIP-seq experiments. A quantitative example: the silenc-
ing mark histone H3 lysine 27 trimethylation, which enriches 
around gene regulatory regions, is represented at the time of this 
writing by 403 ChIP-seq data sets in ENCODE (Encyclopedia 
of DNA Elements) and ≈2000 to 3000 publications in PubMed 
(an exact count of publications is tough given cavalier nomen-
clature); those numbers for H3 K27 acetylation, a euchromatic 
mark (note: on the same residue of the same protein), were 384 
ChIP-seq datasets and ≈500 publications. In contrast, a recently 
Figure 1. Occupancy of histone marks varies between cell types. Circos plot of mouse chr19 shows (A) repressive H3K27me3 and (B) 
active H3K4me3 peaks across different tissues. Color-coding of tissues (outside to inside): heart (red), cerebellum (blue), kidney (yellow), 
liver (green), thymus (orange), testis (dark red), and spleen (light blue). The black track represents mm10 gene density on chromosome 19. 
Data are from the ENCODE (Encyclopedia of DNA Elements) database.
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identified succinylation on human histone H3 K79, also found 
to enrich in the transcription start sites of active genes, has 1 
publication and 1 ChIP-seq data set.32 When examining a new 
PTM, no good antibody, and no tractable cell system for trans-
genesis of a tagged surrogate, means no genome-wide address 
book, which means, for the present, the given modification is 
assumed to be noise. That histone modifications cannot be un-
equivocally examined by genetic approaches (ie, by mutating a 
residue in the gene and studying the protein) is the reason why 
they are alternatively so frustrating and interesting.
What about other changes in protein levels in the nucle-
us? The first attempts to understand proteomic remodeling of 
the cardiomyopathic nucleus were conducted in hamsters.33 
These early studies did not directly measure histone PTMs—
although they (the PTMs) likely were reflected in the electro-
phoretic patterns reported in these investigations—because of 
the absence of accurate and quantitative mass spectrometry 
of proteins and PTMs. More recently, quantitative analysis 
of nuclear proteins34 or chromatin-associated proteins in the 
heart revealed the proteins regulating cardiac epigenomes7 
and described changes in histone protein isoform stoichiom-
etry8 in the setting of pressure overload hypertrophy, yet these 
studies did not characterize histone PTMs. Renal nuclear pro-
teomes have also been explored,36 with physiological impli-
cations for cardiovascular disease. Across eukaryotes, ≈500 
post-translational individual modifications have been identi-
fied just on the core nucleosome particle.22 Few of these have 
been identified, much less quantified and proficiently inter-
rogated, in the cardiovascular system (most studies, to our 
knowledge, of histone PTM in the cardiovascular system rely 
on commercially available antibodies). Recent studies have 
used large libraries of histone modifications, in some cases 
representing >100 different nucleosome combinations (note: 
these are discrete, tailored nucleosomes with known histone 
post-translational modifications, in contrast to the total list of 
histone modifications, for which it is rarely known whether 
Figure 2. Chromatin conformation capture data reveal similarities in chromatin organization between cell types. A, Representative 
contact matrices from 14 human tissues (A), and their A/B compartmentalization profiles (B), demonstrate similarities at the scale of 
topologically associated domains (TADs) and compartmentalization. AD indicates adrenal gland; AO, aorta; BL, bladder; CO, prefrontal 
cortex; HC, hippocampus; LG, lung; LI, liver; LV, left ventricle; OV, ovary; PA, pancreas; PO, psoas muscle; RV, right ventricle; SB, small 
bowel; and SX, spleen. Black track represents mm10 gene density on chromosome 19. Data are from the ENCODE (Encyclopedia of DNA 
Elements) database. Adapted from Schmitt et al21 with permission. Copyright ©2016, the Authors.
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the modifications are happening on the same nucleosome, let 
alone in the same copy of the histone, with the exception of 
proteomic studies on intact proteins37), to investigate the abil-
ity of particular histone PTM combinations to influence the 
activity of human ATP-dependent chromatin remodelers.38 
These libraries39 allow for the effects of individual recombi-
nant nucleosomes with designer histone modifications (and 
combinations of modifications) to be tested in vitro for their 
ability to influence a host of chromatin properties, such as the 
binding preferences for transcription factors or chromatin-
modifying enzymes.
Role of Histone-Modifying Enzymes 
in Cardiovascular Physiology and 
Pathophysiology
Investigations into the enzymes responsible for depositing and 
removing histone modifications have demonstrated striking 
phenotypes in a range of cardiovascular syndromes. Histone 
deacetylases (HDACs) are one of the most extensively studied 
families of histone-modifying enzymes in the cardiovascular 
system. HDACs consist of 4 families, each with distinct iso-
forms which in turn have distinct histone and—in some cas-
es—nonhistone targets, distinct cellular locations and distinct 
biological functions. Inhibition of HDACs has been shown 
pharmacologically (eg, with trichostatin A or valproic acid) to 
prevent proliferation of vascular smooth muscle cells40,41 (with 
implications for atherosclerosis42), to attenuate hypertension,43 
to ameliorate ischemic/reperfusion injury and postischemic re-
modeling,44–47 and to block cardiac hypertrophy in the setting of 
heart failure.48–50 Molecular dissection of these phenomena, par-
ticularly in the setting of cardiac growth, have revealed HDACs 
to be powerful hypertrophic modulators: loss of HDAC9 leads 
to prodigious cardiac growth,51 HDAC4 and 5 regulate CamKII 
(calcium/calmodulin-dependent protein kinase II)-dependent 
gene regulation,52,53 HDAC2 regulates GSK3β (glycogen syn-
thase kinase 3 beta)-Akt–dependent fetal gene activation in hy-
pertrophy,54 to name just a few examples. Indeed, the literature 
on the role of HDAC targeting by drugs or genetic manipulation 
in the cardiovascular system is sufficiently vast to devour entire, 
authoritative reviews articles.42,48,55,56
Class III HDACs are also known as sirtuins and have been 
shown to exert powerful effects in the cardiovascular system 
after their initial identification and association with longevity in 
yeast. There are 7 sirtuin isoforms, each with varied subcellular 
localization and some of which, such as sirtuins 1, 2, 6, and 
7, localize to nucleus and thus are poised to use DNA-bound 
histones as substrates, including in the heart.57 Multiple sirtuin 
isoforms have been shown to facilitate DNA repair through ho-
mologous recombination. Unlike other HDACs, sirtuins require 
nicotinamide adenine dinucleotide as a cofactor for activity. 
Intriguingly, these proteins have been shown to participate in 
an isoform-specific manner in myocardial ischemia, oxidative 
stress, apoptotic cell death, and cardiac hypertrophy.57 Sirtuin 
isoforms have also been shown to exert salubrious effects on 
fatty acid, amino acid, and glucose metabolism in mouse stud-
ies, which have led to clinical trials.58 A search at clinicaltrials.
gov with the keywords cardiovascular disease and epigenetics 
revealed 29 studies in the active or recently completed phase. 
These studies range in their employment of epigenetic measure-
ments or interventions. For example, some describe measuring 
epigenetic end points in response to treatments targeting known 
cardiovascular risk factors in common cardiovascular disease 
(eg, Epigenetic Reprogramming of Monocytes in Patients With 
Coronary Atherosclerosis, which measures epigenetic marks 
in the promoters of proinflammatory cytokines and chemo-
kines in monocytes). Another example is a trial targeting rare 
genetic diseases with epigenetic manifestations in the cardio-
vascular system (X-chromosome Inactivation, Epigenetics and 
the Transcriptome), which measured DNA methylation, his-
tone PTMs, and coding/noncoding RNAs expression in blood, 
white cells, and other tissues. Other examples investigate use 
of hypomethylating agents, including 5′azacytidine and 5-aza-
2′-deoxycytidine, in adult patients with acute myeloid leuke-
mia and atrial fibrillation (Action of the Vidaza on the Atrial 
Fibrillation) or study DNA methylation as a marker for high 
blood pressure in the setting of pregnancy (Observational Study 
of Epigenomic Dysregulation in Preeclampsia-Associated 
Chronic Hypertension). The Human Epigenetic Drug Database 
(hedds.org) is a useful, searchable resource for information on 
epigenetic drugs, their targets, and associated data sets includ-
ing, when relevant, links to clinical trials. Several epigenetic 
drugs are Food and Drug Administration approved for clinical 
use, including HDAC inhibitors and DNA methyltransferase 
(DNMT) inhibitors,59 and several of these have been explored in 
cardiovascular disease (this review60 also includes an extensive 
summary of microRNAs targeted for therapeutic manipulation 
by pharmaceutical companies).
Histone acetyltransferases also constitute a large family of 
genes and have numerous nuclear and non-nuclear substrates 
(with type A being nuclear and type B being non-nuclear, 
mainly cytoplasmic) and have been characterized with vary-
ing degrees of specificity in cardiac and vascular cells.56,61,62 
One of the best characterized histone acetyltransferases is 
p300 which, in addition to its common residence at enhancer 
elements, has been shown to regulate genes that inhibit en-
dothelial cell inflammation in the setting of atherosclerosis63 
and to attenuate salt-induced hypertensive heart failure64 and 
agonist-induced cardiac hypertrophy65 (the males absent on 
the first histone acetyltransferases has similar antihypertro-
phic actions when overexpressed in the mouse66).
The histone methyltransferase SET domain containing 2 
was recently shown to be essential for myoblast differentiation 
in a process involving modification of histone H3K36 trimethyl-
ation.67 SET and MYND containing histone methyltransferase 
(Smyd; a family with 5 isoforms of varying tissue expressivity) 
family member Smyd1, which is restricted to striated muscle, 
has been shown to participate in cardiac phenotype through 
loss-of-function studies in the adult heart, which resulted in hy-
pertrophy, dilation, and derepression of some cardiac disease 
genes.68 Although Smyd1 localizes to the nucleus and interacts 
with chromatin in the adult heart68 (and has been shown to reg-
ulate H3K4me3, an activating mark, in reconstituted systems70; 
mice with Smyd1 depletion in adulthood exhibited sustained 
H3K4me3 levels68; however, supporting the existence of alter-
native substrates for Smyd1 and indicating the existence of al-
ternative proteins capable of maintaining H3K4me3 in cardiac 
myocytes), a substantial portion of the protein is non-nuclear. 
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This non-nuclear population of the protein has also been im-
plicated in adult cardiac function (along with another family 
member Smyd271) and heart development.72–74 A different SET 
family protein, G9a (also known as euchromatic histone ly-
sine methyltransferase 2), has been shown by loss-of-function 
studies to play a key role in adult cardiac phenotype: induc-
ible MerCreMer-dependent depletion resulted in cardiac hy-
pertrophy, modestly depressed ejection fraction, and fibrosis 
through a mechanism that involves targeted derangement of 
multiple histone methylation marks (including H3K9me2/3 
and H3K27me3) at genes involved in cardiac function.75 SET7 
was shown in a human microvascular endothelial cell line to 
regulate target gene (IL-8 [interleukin 8] and HMOX1 [heme 
oxygenase 1]) expression in a H3K4me1-dependent and -inde-
pendent manner.76 Intriguingly, this process is tightly linked to 
glucose levels, demonstrating a metabolic sensing mechanism 
on chromatin.77 On the removal side of methylation, genetic 
loss or augmentation of the histone demethylase JMJD2A, 
respectively, blocked or exacerbated cardiac hypertrophy in 
mice.78 A recent pharmacological study showed that inhibition 
of histone methylation at H3K9 with the compound chaetocin 
(which targets the enzyme [SU(VAR)3–9] responsible for con-
version of H3K9me2 to H3K9me3) attenuates some aspects 
of salt-induced cardiac dysfunction (survival rate, fractional 
shortening, and fibrosis)—while not affecting pathological 
gene regulation and only modestly impacting hypertrophic 
growth—in part through diminished H3K9me3 at repetitive 
elements and mitochondrial genes.79
The polycomb repressive complex (PRC) is one of the 
best-studied gene silencing complexes (responsible for 
H3K27me3 deposition) and has been implicated—usually 
through the actions and genetic disruption of one or more of 
its components—in a wide variety of higher phenotypes in 
mammals. In the cardiovascular system, the Ezh subunits 1 
and 2 were shown to be differentially involved in cardiac de-
velopment and regeneration: both were necessary for normal 
development, with Ezh1 but not 2 being required for neonatal 
heart regeneration and with Ezh1 but not 2 being capable, 
via overexpression, of promoting regeneration in the hearts 
of mice aged outside the established neonatal regenerative 
period,80 suggesting that features of myocyte proliferative/
regenerative plasticity may be revived through histone-mod-
ifying enzymes. Ezh2 stabilizes forming blood vessels in the 
mouse embryo,81 and pharmacological inhibition of Ezh2 
(and some H3K27me3 target loci) improved outcomes in 
hindlimb ischemia.82 Some naturally occurring compounds 
target histone-modulating enzymes (and nonhistone lysine 
residue-containing proteins) and have substantial in vivo 
benefit in conditions, such as cancer.83,84 Because many of 
these compounds are present in diets shown epidemiologi-
cally to promote cardiovascular health (such as cruciferous 
vegetables), part of this effect may be through actions to pro-
mote—at the subcellular level and across organs—favorable 
epigenomic health.
Although the histone isoforms and even specific residues 
targeted by individual enzymes have often been worked out 
in reconstituted systems in vitro, such information is almost 
universally lacking from such studies in animal models of the 
cardiovascular system (this observation is also true, inciden-
tally, for most studies of acetylating/deacetylating and meth-
ylating/demethylating enzymes in noncardiovascular systems 
when examined at the organ level in animal models). It is also 
important to note that many of these histone-modifying en-
zymes target nonhistone substrates that have no direct relation-
ship to gene expression or epigenetics but yet exhibit powerful 
effects on complex organ level phenotypes (cardiovascular ex-
amples include Smyd on titin,71 HDACs on myofilaments,85 
and HDAC family members of the sirtuin class which regulate 
many substrates in mitochondria and cytosol57).
This leads to a couple interesting questions about chro-
matin-modifying enzymes in the cardiovascular system: First, 
what are the principles that allow for coordination of the vari-
ous writers, readers, and erasers in the given cell type at any 
time (by this it is meant: how do the histone modifiers them-
selves get turned on or off, up or down, and when turned on, 
how do they compete for influence over gene expression in 
a reproducible manner?). And second, how do the cadre of 
expressed-at-any-given-time enzymes decide which nucleo-
somes to modify (ie, how is targeting accomplished, because 
most histone-modifying enzymes do not have DNA sequence-
targeting motifs)? One approach to answer these questions 
would be to identify intermediate indices of epigenomic func-
tion like accessibility and structure, designing interventions 
that modulate these indices.
ATP-Dependent Remodeling of  
Chromatin: Inducing and Participating  
in Cardiovascular Diseases
ATP-dependent chromatin remodeling enzyme complexes use 
the energy from ATP to translocate DNA through the nucleo-
some. That is, the ATP-dependent chromatin remodelers re-
position nucleosomes along the genome according, in part, to 
cues harbored in the spectrum of histone tail PTMs, thereby 
enabling fundamental genomic processes, like transcription, 
nucleosome assembly/disassembly, mitosis, meiosis, and 
chromosome segregation. One of the most studied of these 
complexes is the SWItch/sucrose nonfermentable complex, 
originally identified in yeast (and known to have >10 protein 
components) and its mammalian cousin the brahma-asso-
ciated factor complex (itself composed of >10 protein com-
ponents, some of which exhibit tissue-specific expression). 
Models for the actions of these remodelers are informed by 
protein crystallography studies, in vitro biochemical assays, 
and ChIP-seq–based genome-wide measurements and are thus 
highly developed and can help to explain the observed dyna-
mism of chromatin in development, between cell types and 
in stimulus response.86–88 Because presence of bivalent marks 
at a given locus are necessary but not sufficient to specify a 
bivalent locus, recent studies have focused on evaluating the 
role of ATP-dependent chromatin remodelers in this process.89 
Studies in the cardiovascular system have examined the role 
of these complexes in tissue level phenotypes by genetic ma-
nipulation of the ATPase subunits of the brahma-associated 
factor complex, Brm (Brahma), or Brg1 (brahma-related gene 
1, a.k.a. Smarca4). For example, genetic disruption of either 
of these molecules alone had no effect on retinal angiogenesis 
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in neonates, exercise-induced angiogenesis in adult skeletal 
muscle, or tumor angiogenesis, whereas mice with disrup-
tion of both Brm and Brg1 after birth exhibited fatal vascu-
lar malfunction in the heart and gut during the early postnatal 
period90 (similar context-dependent functional redundancy, 
and lack thereof, was observed between Brm and Brg1 in 
the vascular endothelium, wherein disruption of both pro-
teins in endothelial cells was required to observe tissue level 
defects91). Brg1 has been shown to be involved in zebrafish 
myocyte proliferation and cardiac regeneration,92 mesoderm, 
and hence cardiomyocyte, differentiation in cell culture, in 
part by modulating enhancer activity,93 whereas both Brg1 
and Smarca3 (a.k.a. brahma-associated factor 60c, another 
brahma-associated factor complex member) are required for 
normal heart development in mouse94–96 (incidentally, Brg1 
was found to be downregulated in adult murine hearts and re-
expressed, concomitant with the myosin heavy chain isoform 
switch [α to β] associated with cardiac pathology; blocking 
Brg1 upregulation in the adult prevented this molecular event 
and attenuated hypertrophy95). Early formation of vascula-
ture and erythropoiesis in mouse is dependent on Brg1 but 
not Brm in hematopoietic and endothelial cells,97 implying 
functional distinction between complexes seeded with these 
different ATPases during cardiovascular development (a simi-
lar conclusion was made from genetic disruption in smooth 
muscle cells98), a functional involvement that may extend into 
adulthood in the setting of endothelial injury and presumably 
disease.99
Multifunctional Role of DNA  
Methylation in Chromatin Biology and 
Cardiovascular Phenotypes
DNA methylation is dynamic during vertebrate development, 
where it reinforces cell fate decisions and controls imprinting, 
or the dependence of gene/protein expression (and associated 
phenotypes) on whether a given version of a gene is expressed 
from maternal or paternal allele. Unlike histone modifica-
tions, which can occur on any number of different amino ac-
ids apparently without heed to locale (ie, without clear DNA 
consensus motifs), DNA methylation targets a single residue, 
cytosine, usually in a single context (ie, when followed by a 
guanine, so called CpG dinucleotides; recent evidence sug-
gests, however, that this too may be an oversimplification 
as non-CpG DNA methylation, so-called CpH methylation 
[where the H connotes A, T, or C] occurs in some cells,100 such 
as neurons [where it may account for 25% of methylation], 
although this has only begun to be explored in the cardiovas-
cular system101,102). Also contrasting with the plethora of pro-
teins controlling histone PTM, DNA methylation is directly 
added or removed by a narrow suite of enzymes: maintenance 
(DNMT1) and de novo (DNMT3a and DNMT3b; DNMT2 
modifies RNA and DNMTL is a catalytically inactive regula-
tory component of the methylation machinery) methyltrans-
ferases which establish methylation patterns after mitosis and 
replication and alter the pattern of methylation during organ-
ismal development and disease, respectively. Demethylation 
of DNA occurs in part via nonenzymatic means during rep-
lication, as well as during normal and pathological condi-
tions in nondividing cells. Conversion of 5-methyl-cytosine to 
5-hydroxymethylcytosine is catalyzed by the 10-11 transloca-
tion methylcytosine dioxygenase 1 family of enzymes—an ac-
tive, selective process. The 5-hydroxymethylcytosine is a less 
stable modification, prone to nonenzymatic conversion to (un-
modified) cytosine, and has thus been proposed as a molecular 
beacon of genes switching from off to on. DNA methylation 
patterns are erased and re-established transgenerationally, but 
this process seems to involve faithful perpetuation of methyla-
tion marks along the genetic lineage, that is, from parent to 
progeny (further evidence of this phenomenon can be seen in 
inbred mouse strains, whose DNA methylation landscapes are 
epigenetically preserved within a genetic lineage while being 
stably distinct between lineages103,104).
Bisulfite sequencing is the method for unequivocal deter-
mination of methylation status (note: all methods for DNA 
methylation analysis are in symbiosis with suites of infor-
matics tools105). Broadly construed, DNA methylation in CpG 
islands (regions of genome with high frequencies of the dinu-
cleotide, which incline toward promoters) and shores (areas 
around said islands) tends to be associated with gene silenc-
ing.106 Conversely, the bodies of mRNA-encoding genes tend 
to be methylated, without an established correlation allow-
ing prediction of expression. Other methods for large scale 
analysis of DNA methylation include methylation immuno-
precipitation (which has been used to identify methylation-
dependent regulation of atherosclerotic risk in humans107) and 
DNA methylation arrays (notably the Illumina 450 chips), the 
latter of which has been extensively deployed in humans to 
characterize methylation patterns associated with a host of 
pathophysiological conditions including cancer,108 high blood 
pressure,109 body mass index and obesity,110,111 atrial fibrilla-
tion,112 inflammation,113 and death.114 Perhaps, because of cost 
and technical demands, reduced representational bisulfite se-
quencing (or much more expensive whole genome bisulfite 
sequencing) has been applied to a smaller list of diseases. 
Such data from mice, however, show that DNA methylation 
plays a powerful role in heritable differences in response to 
metabolic syndrome103 and may contribute to catecholamine-
induced cardiac pathology.104 DNA methylation and hydroxy-
methylation abnormalities have been found in animal115,116 
and human117,118 heart failure, associated with changes in 
expression of pathological genes. Work from mouse cardio-
myocytes suggests that DNA methylation largely obeys chro-
matin structural features of A/B compartmentalization (itself 
defined based on gene density, histone marks, and other 
features of open chromatin; see section below on chroma-
tin structure), wherein dynamics of DNA methylation during 
lineage commitment are enriched in A (active) compartments 
and genetic disruption of DNA methylation (via DNMT3a 
and 3b knockout) does not alter compartmentalization.102 
This observation supports a passive relationship between 
DNA methylation and chromatin structure, at least in the for-
mation phase.
What is the import that methylation patterns are associ-
ated with complex human phenotypes? One method through 
which DNA methylation has its molecular effects is to rein-
force prevailing chromatin landscapes by preventing accessi-
bility and facilitating compaction (in promoters, as mentioned 
above, and in X chromosome inactivation, where it conspires 
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with histone H3K27me3 to silence expression of 1 of the 2 
X chromosomes in females119,120); another is to favor relax-
ing of chromatin and transcription (as in gene bodies). These 
opposing effects must require the intervention of discriminat-
ing factor(s), perhaps including methyl-CpG binding proteins, 
but this field currently wants for established rules and actors. 
One investigation121 demonstrated that MeCP2, a methyl-CpG 
binding protein, is reversibly downregulated in a mouse model 
of pressure overload (when the aortic banding was removed, 
MeCP2 expression was restored; similar observations in pa-
tients with LVADs [left ventricular assist device] suggest this 
process may be operative in humans). These findings suggest 
that the actions of DNA methylation may be modulated in the 
diseased heart at multiple levels, including methylation, de-
methylation, and reading of methylation. Another mode of ac-
tion is through trans effects, whereby a methylation event can 
regulate the expression of a gene in a distal region of the ge-
nome (ie, far away from the actual CpG in question). Studies 
from human cardiac development reveal an enrichment of reg-
ulatory elements, including DNA methylation sites, in regions 
of genetic variation associated with heart disease,122 support-
ing a molecular link between chromatin regulation and ge-
netic variation in the context of pathological phenotypes. By 
regulate, it is meant here that the methylation event is shown 
to correlate—with genome-wide statistical significance—with 
the expression of a gene, a methylation quantitative trait locus. 
This regulation may take the form of enhancer element forma-
tion/modification (discussed below) or other as-yet uncharac-
terized chromatin structure effect.
The prevalence of cancer123 and congenital heart dis-
ease124 in humans is associated with mutations in genes 
encoding proteins that modify chromatin, such as his-
tone-modifying enzymes (writers, erasers, and readers). 
Furthermore, these complex diseases are often associated 
with global changes in DNA methylation. In some cases, the 
genetic or epigenetic lesion occurs in a gene whose aberrant 
function can exert a dominant role in disease pathogenesis. 
In other cases, these epigenomic changes may instead be 
general hallmarks of perturbed cellular function, whereby 
the normal parameter space for gene expression is expand-
ed, facilitating dysfunction of multiple cellular processes. 
For many observations on histone PTMs and DNA meth-
ylation in cardiovascular disease, the train or snow leopard 
question remains unanswered.
Role of Noncoding RNAs in Chromatin 
Function and Cardiovascular Physiology
It is now appreciated that most of the genome is transcribed, 
if only a small portion of that transcriptome encodes mRNA 
destined for translation, with intriguing differences in this 
noncoding transcriptome across cell types and after pathologi-
cal insult. Noncoding RNA biology is a specialized discipline 
unto itself, with new species of RNA—ascribed really cool and 
sometimes bizarre functions—identified seemingly endlessly 
and will not be extensively reviewed herein (excellent reviews 
on the roles of various noncoding RNAs in cardiovascular bi-
ology have emerged125–128). Of particular interest to chromatin 
biology, however, is the concept that long noncoding RNAs 
(lncRNAs) may participate in gene regulation by modulating 
chromatin structure.
lncRNAs have been proposed as a potential mechanism 
for how different chromatin marks are deposited—specifically 
and reproducibly—across the genome. One of the best-stud-
ied lncRNAs, a general definition of which is an RNA >200 
nucleotides with no discernable open reading frames (an ex-
ception to this being the presence in some lncRNAs of open 
reading frames which have been shown to produce micro-
peptides that go on to regulate key intracellular processes in 
cardiovascular cells129,130), is Xist, which is centrally involved 
in X chromosome inactivation. Xist is transcribed from and 
acts in cis to silence the X chromosome through a process 
that recruits, via direct binding of Xist to the proteins, the 
PRC2 complex, and YY1. A depositor of histone H3K37me3 
silencing marks and transcriptional repressor, respectively, 
these proteins in turn compact the X chromosome and prevent 
further transcription.120,131 This model—lncRNA binding to a 
specific region of chromatin and recruiting histone-modify-
ing enzymes—is appealing because it solves the problem of 
DNA sequence recognition, of which many histone modifiers 
are incapable. Another well-characterized lncRNA that binds 
PRC2 subunits is Hotair, involved in gene silencing in mam-
mals and shown to regulate chromatin in trans outside of the 
context of X inactivation.132 These studies led to a gold rush 
on PRC2-interacting lncRNAs, which have been estimated to 
range in number from hundreds to thousands in mice133 and 
humans.134 The general properties, if they exist, through which 
these lncRNAs couple PRC2 to chromatin are the focus of 
continued investigation.135,136 It may be that the genes for these 
molecules are distributed across the genome and the lncRNAs 
in turn all act in a local manner to recruit and modulate chro-
matin machinery to a given gene expression environment.137 
Yet there are clear limitations were the cell to attempt to repeat 
this process with other lncRNAs: physiological transcriptional 
profiles in adult cells do not involve turning on or off entire 
chromosomes, with genes temporally coregulated often resid-
ing on different chromosomes (each of which, in this model, 
would require its own lncRNA, although 3-dimensional chro-
matin environments may allow transcription factories to form 
bringing multiple mRNA-coding genes into a neighborhood 
governed by a single lncRNA) and beset by numerous histone 
modifications. Reflecting this fact, the spectrum of lncRNA 
functions has expanded120,138 to include actions in trans (ie, 
targeting other chromosomes) as well as cis to enhance tran-
scription, to block it, to scaffold chromatin interactions, and 
to aggregate microRNAs (thereby making them unavailable to 
regulate mRNAs).
Initial investigations of lncRNAs in the heart revealed in-
volvement in developmental growth and maturation. Fendrr 
binds both PRC2 and the activating complex Trithorax group/
MLL in mesoderm, its depletion leading to impaired cardiac 
and chest wall development.139 Braveheart, another meso-
derm-associated lncRNA, binds the Suz12 subunit of PRC2 
and is required for proper differentiation of embryonic stem 
cells into cardiac precursors.140 Also involved in cardiac de-
velopment is the lncRNA Upperhand that regulates the Hand 
2 locus in cis by facilitating chromatin modifications (super 
enhancer maintenance) and RNA pol II elongation.141 Other 
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lncRNAs have been discovered to play a role in disease-
associated gene regulation. Chaer binds the Ezh2 subunit 
of PRC2, and its genetic manipulation leads to alteration in 
H3K27me3 levels around pathological genes and cardiac hy-
pertrophy in the mouse.142 An antisense transcript in the β-
MHC (beta-myosin heavy chain) locus was found to associate 
with that locus in a manner independent of the PRC subunit 
EZH2 in the setting of pressure overload.143 Interestingly, that 
same paper showed the EZH2 interaction with chromatin was 
regulated by the noncoding RNA pri-miR-208b, hinting at a 
broader role for noncoding RNAs in regulating chromatin.128 
Some lncRNAs seem to exert their effects on gene regulation 
through interaction with chromatin remodeling complexes, 
as is the case for Mantis, a lncRNA discovered in macaque 
and shown to regulate endothelial angiogenesis in a manner 
involving interaction with BRG1.144 Similarly, the cardiac-
specific lncRNA Myheart binds and inhibits the actions of 
BRG1, thereby regulating expression of myosin heavy chain 
expression, along with other genes. Myheart is downregulated 
by pressure overload stress and its transgenic restoration pro-
tects against overload-induced hypertrophy.145 Interestingly, 
lncRNAs like Malat1 in vascular tissues146 and Chast in car-
diac tissues147 are nuclear localized and regulate expression 
of nearby genes although it remains to be tested whether they 
accomplish these actions through recruitment of chromatin 
complexes. In the field of cholesterol metabolism, 2 recent 
lncRNAs have been discovered that exert powerful effects of 
lipid levels and atherosclerosis in vivo: LeXis,148 expressed in 
the liver, directly controls genes involved in cholesterol bio-
synthesis, consequently modulating plasma cholesterol lev-
els, and MeXis,149 expressed in macrophages, regulates genes 
involved in cholesterol efflux (both lncRNAs were found to 
operate through chromatin based on subcellular localization, 
accessibility assays, and transcriptional regulation).
Discovery analyses in a mouse model of pressure over-
load revealed the expression profile of cardiac lncRNAs,150 
determining their extent of enrichment in this tissue when 
compared with tissues of distinct developmental origin (liver 
and skin) and determining changes between embryonic, adult, 
and diseased noncoding transcriptomes (nota bene: only a few 
of the developmentally silenced lncRNAs were re-expressed 
with disease, in contrast to the fetal gene program151 docu-
mented for mRNAs). Likewise in myocardial infarction, the 
recovery/injury/remodeling period was found, in mice, to be 
associated with changes in lncRNA expression (incidentally, 
the lncRNAs were also found to reside near chromatin marks 
associated with transcriptional enhancement), some of which 
(the lncRNAs) were subsequently shown to modulate expres-
sion of mRNA-encoding genes known to participate in basic 
cardiac function.152 Studies from humans have charted dif-
ferences in lncRNA expression between fetal and adult car-
diomyocytes, linking their expression with known enhancer 
marks associated with protein-coding RNA transcription (eg, 
H3K4 methylation).153
What is known about lncRNAs in the cardiovascular sys-
tem is that they can be cell type specific, often lack extensive 
sequence conservation across species (although they may be 
conserved at the level of secondary structure), can regulate 
transcription (probably mostly in cis), and can correlate with 
histone PTMs, binding some of the histone-modifying com-
plexes, PRC2 in particular. It is unknown to what extent ln-
cRNAs can act at a distance (beyond, say, a few kilobases from 
their own site of transcription), the role of chromatin structure 
to coordinate such actions (evidence from X inactivation sug-
gests that local chromatin environment—rather than DNA 
consensus motifs—facilitates Xist binding, PRC recruitment, 
and inactivating activity131), if they bind directly to chromatin 
and DNA (perhaps involving triple helix formation154,155), and 
whether they are sufficient to coordinate the locus-specific ac-
tivities of chromatin modifiers through a model in which mul-
tiple lncRNA genes, by virtue of their evolutionary distribution 
at key sites across the genome, establish local neighborhoods 
of regulation at which they recruit—or repel, according to 
wont—histone modifiers and polymerase machinery.
Cardiovascular Development- and Disease-
Associated Enhancer Elements
Enhancers are regions of DNA that promote the transcription 
of other regions of DNA.156–158 A contemporary synthesis on 
how this works: specific histone PTMs (eg, histone H3K4me1 
and H3K27ac; some histone isoforms, such as H3.3 and H2az, 
contribute to enhancer activity; enhancers are now thus com-
monly identified by genome-wide ChIP-seq experiments) 
decorate regions of DNA that need not be—although may be 
(see below)—themselves transcribed, which in turn recruit 
binding of enhancer-associated proteins (eg, lineage relevant 
transcription factors, RNA pol II, and coactivator proteins, 
such as p300 and Mediator) and interact in 3 dimensions 
with the genes whose expression they enhance. This region 
of DNA, the appropriately demarcated histones, and any as-
sociated proteins together constitute the enhancer which is 
often validated as such by showing that either (1) its genetic 
disruption interferes with expression of its target gene or (2) 
that the enhancer DNA sequence can drive developmental and 
lineage appropriate transcription through a cell- or organism-
based reporter assay. In the absence of chromatin confor-
mation data, enhancers are usually assumed (and tested) to 
regulate the nearest downstream gene. Somewhat counterin-
tuitively, then, enhancers tend to reside in areas of relative nu-
cleosome depletion (not, strictly speaking, in areas devoid of 
nucleosomes), such that enhancers can be identified by open 
chromatin assays (eg, DNAse I hypersensitivity or ATAC) fol-
lowed by DNA sequencing. A subgroup of enhancers, called 
super enhancers,159 has been classified based on the observa-
tion that the aforementioned enhancer features at times occur 
multiple times in close proximity to each other. Super enhanc-
ers can exhibit augmented transcriptional activation potential 
and thus may represent a distinct structural property of cell 
type–specific chromatin.160 Further specification of enhancer 
behavior includes delineation of poised (those ready for pro-
moting transcription of their targets) versus active (those ac-
tually so promoting) enhancers, which can be distinguished 
by the presence of silencing histone marks (and the enzymes 
that deposit them) at poised enhancers and their absence (con-
comitant with the presence of greater levels of RNA pol II) at 
active enhancers.156–158
It has more recently become apparent that some enhancers 
may themselves be transcribed161 and may thus operate in the 
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RNA form. It could be that this transcription is a goal-directed 
process in the normal way we think about RNA doing things 
in the cell: the enhancer RNAs may have gene regulatory or 
other functions. It may also be that the enhancer RNA syn-
thesis is a by-product of enhancer DNA in close apposition 
to churning transcription factories and serves no subsequent 
end and that its transcription serves the end of keeping a tran-
scription factory churning and poised for ready enlistment in 
production of other RNAs that do serve subsequent ends (as 
RNAs). This fascinating concept of chromatin biology is an 
active area of investigation.162 Studies have begun to emerge 
examining the role of enhancer transcription in select cardio-
vascular processes, such as cardiac conduction163 and endothe-
lial cell stress response.164 Active endothelial cell enhancers, 
defined by H3K4me2 and H3K27ac binding (plus some en-
hancer RNA transcription), exhibited altered transcription 
factor binding in human aortic endothelial cells after expo-
sure to oxidized phospholipids.164 Intriguingly, SNPs (single 
nucleotide polymorphisms) associated with cardiovascular 
disease were over represented in these enhancers, suggesting 
a molecular scale explanation for how the former influences 
transcription and phenotype, a property that may be a com-
mon feature of enhancers across cell types and species.165
p300 occupancy has been used to identify enhancers in 
the developing mouse heart (embryonic day 11.5), many 
of which were found to exhibit tissue-specific activity.166 
A similar approach was used to characterize enhancers 
in fetal and adult human heart tissue (of note, 48% of the 
enhancers were the same in fetal and adult human hearts; 
when comparing fetal mouse to fetal human, the overlap was 
21%),167 revealing functional elements that may participate 
in human cardiac gene regulation. Angiotensin II–induced 
vascular growth, a key component of atherosclerosis, was 
found to proceed via dynamic utilization of super enhanc-
ers in human cells through a process that involves complex 
interplay among noncoding RNAs, chromatin readers, and 
transcriptional machinery.168 A theme of developmental pro-
cesses being redeployed—not wholesale, but in a selective 
manner—in the disease setting may also play out for enhanc-
ers: regulatory elements marked by H3K27ac are specified 
in part by the master cardiac transcription factor GATA4 
during development and some of these regions, devoid of 
GATA4 in healthy adult heart, are revisited by the protein on 
pathological stimulation, contributing to disease-associated 
gene expression.169 Pursuing this concept more directly in a 
complementary model, it has also been shown that cardiac 
enhancers undergo altered regulation by disease-associated 
transcription factors after pathological stress.170 The histone 
modification reader BRD4 binds super enhancers that are as-
sociated with cardiac disease genes. Interestingly, this pro-
cess is finely tuned to differentially modulate association of 
BRD4 with these disease genes while leaving housekeeping 
genes unaffected, a process controlled in part by microRNA-
dependent titration of BRD4 levels.171
Unexpected Cell Type–Specific  
Functions of Chromatin
The rapidly dividing phenotype of cancer has allowed re-
searchers in this field to identify epigenetic clones172: lineages 
of cells outwardly genetically identical that differ based on 
semistable, transmissible chromatin features. All cardiac 
myocytes and vascular smooth muscle cells are not the same, 
which means that although these cells do not proliferate and 
differentiate like cancerous cells do, it is reasonable to hy-
pothesize that developmentally endowed epigenetic clones 
exist and contribute to organ level phenotypes in the adult. 
Indeed, distinct clonal populations (arising from a common 
progenitor in development, rather than from a resident adult 
stem cell) of cardiac cells contribute to different anatomic 
and functional features of the adult organ173–178 (recent single 
cell studies have revealed these distinct myocyte populations 
to indeed exhibit distinct transcriptomes179,180)—epigenetic 
dissection of these populations may well reveal epigenetic 
clonality to be an underlying process contributing to this 
observation. The chromatin accessibility assay ATAC-seq, 
which reveals areas of open chromatin, has been applied in 
a single-cell format to a lymphoblastoid cell line, identifying 
subpopulations of cells based on chromatin accessibility.181 
That such variability exists in postmitotic, healthy adult cells 
in the cardiovascular system remains to be demonstrated, but 
the observation of transcriptome variability in these cells, and 
the presence of chromatin accessibility variability in cells 
otherwise phenotypically similar, makes such a conjecture 
not unwarranted.
Chromatin can act like a stress sensor complex, wherein 
there is no single factor controlling changes in disease-asso-
ciated gene expression. Some investigators have described 
excitation–transcription coupling, with the term specifically 
applied to local calcium signals around the nucleus (as dis-
tinguished from global calcium transients involved in myo-
filament contraction) inducing local CaMKII activation and 
HDAC mobilization.182 What if this observation is evidence 
of a more generalized, myocyte-specific sensory apparatus 
on chromatin, that detects local calcium signaling, such as 
that involved in pathological gene activation, from calcium 
involved in contraction and nonetheless critical to influ-
ence gene expression (eg, sustained faster heart rates require 
greater turnover of proteins and thus transcripts)? Various 
pathological cell states, including cardiovascular disease and 
cancer, have been characterized by global changes (eg, that 
revealed by a total cell lysate Western blot or genome-wide 
ChIP-seq signal) in histone modification. One possible reason 
for this unexpected observation was found to include regula-
tion of cellular acidity183: global histone acetylation responds 
to perturbation of cellular pH (lower pH leads to less histone 
acetylation) and cells respond to modulation of histone acety-
lation by modulating pH, a sort of acetate capacitance sys-
tem on chromatin to attenuate large swings in cellular acidity. 
Combined metabolomic and proteomic studies reveal that 
abundance of short chain acyl-CoA donors directly, although 
not indiscriminately, influences the modification of histone 
tails in human cells in culture.184 Indeed metabolic sensing by 
chromatin has been increasingly recognized to underpin car-
diovascular physiology and disease.77
Aberrations in nuclear rigidity and structural integrity 
are associated with diseases like cancer and progeria, some 
of which are driven by so-called laminopathies, arising from 
malfunction of nuclear lamina proteins. Cardiomyopathies 
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resulting from mutations in lamin A/C are one of the best-
studied group of genetic diseases in clinical cardiology and 
have led to clinical trials, although in this context the effects 
on chromatin structure are unclear. Aberrant nuclear mor-
phology, the blebbing of the nuclear membrane because of 
impaired laminar network architecture, is a hallmark of these 
diseases.185 Association of chromatin with the lamina seems 
to be essential for nuclear structure, and disrupting this in-
teraction has detrimental effects on nuclear integrity,186 par-
ticularly in cells subject to mechanical force. These actions 
are coupled to the mechanisms known to regulate chroma-
tin’s role in gene expression, as supported by the observation 
that histone PTM influences nuclear rigidity and membrane 
integrity.187
An unexpected non-nuclear, signaling behavior of not 
just chromatin-modifying proteins but actual intact multi-
molecular slabs of chromatin has been observed in cancer188: 
cytoplasmic chromatin fragments—evaginated nuclear mem-
brane containing DNA and nucleosomes decorated with 
heterochromatin marks—can induce inflammation and cell 
death through cytoplasmic signaling and circle-back tran-
scriptional regulation. An even weirder story: rod and cone 
cells are terminally differentiated, specialized components 
of the retina, the light-sensitive component of the vertebrate 
eye. Evolution has hijacked chromatin in rods (but not cones) 
to serve the transcriptionally unrelated function of focusing 
light in the retinas of nocturnal but not diurnal mammals 
(ie, the organization of DNA in the nucleus forms a physical 
lens),189 thereby providing a meta-function in service of that 
specific cell’s raison d’être.
Different structural units of chromatin establish distinct 
transcriptional environments. It can be helpful to think of 
chromatin itself as a transcription factor or transcriptional 
processor. Transcription does not happen willy-nilly through-
out the nucleus but rather is localized to transcription facto-
ries,190 or areas designated to different forms of transcription, 
such as rRNAs and house-keeping sorts of protein-coding 
mRNAs, separated from stimulus responsive genes and fur-
thermore from transcriptionally silent regions. This happens 
on a nuclear scale as reflected by the observation that tran-
scription tends to happen toward the center of the nucleus 
whereas the periphery is an area of gene silencing. Another 
type of transcription factor-like activity is subchromosomal, 
in the form of chromatin looping, the formation of short- and 
long-range interactions to facilitate gene activation (ie, en-
hancer elements) or repression (ie, insulators or boundary 
elements). Chromatin capture data have revealed that long 
range looping within the epigenome is dynamic and can 
bring together transcription start and end sites in 3 dimen-
sions, perhaps to facilitate efficient cycling of machinery like 
polymerases and transcription factors (Hi-C data support this 
concept for a cohort of genes, Figure 3; Online Table II). This 
principle has been supported with ChIP-seq data from rat 
hearts,192 in which different transcriptional activation profiles 
(pause-release and de novo recruitment) have been described 
in the setting of pressure overload hypertrophy, along with 
accumulation of RNA pol II in transcription end site, perhaps 
reflective of gene looping.
Structure-Function Features of Chromatin  
and Implications for Cardiovascular  
Gene Regulation
Based on insights from chromatin capture and other epigenom-
ic techniques, the organization of the epigenome is thought to 
involve key structural intermediates (Figure 4). What is the 
evidence that chromatin is inherently ordered above the level 
of the nucleosome (where data exists to the atomic—that is sev-
eral angstrom—level2) and below the level of the chromosome 
(where chromosome painting, closer to the scale of microm-
eters, demonstrates compartmentalization193)? The goal of chro-
matin structural studies is to determine: what are the structural 
features between these scales and at what scale(s) are structural 
features functionally important? Next consider the pattern of 
chromatin observed in various cells of the cardiovascular lin-
eage with a quotidian method, such as DAPI (4',6-diamidino-
2phenylindole) labeling: while the pattern of staining is not 
random, there is no obvious reproducible pattern within a class 
of cells (and not shared between 2 classes) to which a functional 
consequence can be intuited (for a nifty exception, see ref 189), 
in contrast to chromosome patterns in mitosis/meiosis which 
definitively exhibit such tell-tale architecture. Fluorescence in 
situ hybridization experiments clearly demonstrated spatial seg-
regation of chromosomes into territories193 while not revealing 
evidence of hierarchical arrangement. Recent higher resolution 
electron microscopy–based imaging of chromatin shows that its 
structure, in both interphase and mitotic cells, rarely achieves 
a scale >24 nanometers in diameter (for reference, the nucleo-
some diameter is ≈11 nm), with distinctions in arrangement be-
tween such cells coming from the density of compaction, which 
the authors interpret to be evidence of an absence of repeating, 
stable, hierarchical structure.194 How do these observations hold 
up in analyses of individual genes and with respect to histone 
post-translational modifications? In the cardiovascular arena, 
combination of Dam-ID and LaminB ChIP-seq (to identify 
loci associated with the nuclear periphery) and fluorescence 
in situ hybridization was used to demonstrate that differentia-
tion in the myocyte lineage involves precise reorganization of 
expressed genes away from the myocyte nuclear membrane, 
itself found to be decorated with the silencing mark H3K9me2, 
and to a lesser degree by H3K9me3 (other silencing marks 
H3K27me2/3 and H4K20me2/3 were not found enriched at the 
periphery in  skeletal myoblasts).195
A prediction of a nonhierarchical model of chromatin is 
that the size of structural elements should be normally distrib-
uted. For chromatin interactions detected by Hi-C, for example 
in cardiac myocytes, this prediction has been shown to be true: 
the number of interactions plotted per locus follows a normal 
distribution, where most locus bins (bin size=5kb) have the 
same number of interactions (≈2500) and a small number have 
very few or very many interactions (see Online Figure IA in 
reference 191). The vast majority of loci interact with a median 
number of other loci, and no privileged structural behavior can 
be assigned to the regions with large interactions (as would be 
a prediction of a scale free or hierarchical topology).
Additional insights from the explosion of chromatin 
capture techniques to determine endogenous interactions 
have been informative.21,196 These studies have characterized 
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features of chromatin organization that are conserved across 
species and cell type (note: method development for analysis 
of chromatin capture data is ongoing and the interpretation 
evolves with it197): topologically associated domains (TADs) 
are regions of chromatin with privileged local interaction; 
TAD boundaries, as nominally implied, demarcate regions 
of the genome where intrachromosomal interactions switch 
from interacting in 1 direction (say 5′ biased) to the oppo-
site; distinct regions are insulated against expression, in part 
by chromatin structural proteins and histone modifications; 
short and long range interactions reproducibly form (ie, the 
structure is not random). The boundaries represent epig-
enomic cornerstones, directing interactions of nearby DNA 
and proteins in alternating directions, in part through the bind-
ing of chromatin structural proteins like CTCF. Cohesin and 
CTCF knockout animals and cells indicate these proteins are 
involved in TAD maintenance,191,198,199 but these proteins alone 
are not the whole story: embryonic stem cells198 with only 4% 
normal CTCF protein levels still exhibited TADs and cardio-
myocytes191 with 20% normal CTCF protein levels exhibited 
sparse, minor changes in TAD boundaries and strength. These 
studies also show that TAD formation/maintenance and A/B 
compartmentalization can be decoupled experimentally as 
loss of cohesin or CTCF did not affect A/B compartmental-
ization. A compartments have more genes and are defined by 
having less interactions than would be expected for a given 
distance (B has more), indicating less compact chromatin. Eu- 
and heterochromatin marks dominate in A and B compart-
ments, respectively. Prevailing evidence suggests that at the 
level of TADs, chromatin architecture is quite similar between 
Figure 3. Chromatin looping. A, Schematic representation of chromatin looping, in this example between transcription start (TSS) and end 
(TES) sites of a gene. The model is an interpretation of chromatin capture data (which shows a decrease in interactions during cardiac pathology) 
and is intended to represent the frequency of a given conformation, not a population effect across cells: left, under normal conditions, loops are 
stably formed; right, because loops are less stable, they are less frequently captured experimentally. B, An example gene displaying this behavior. 
Top is control, middle is CTCF (CCCTC-binding factor) knockout, and bottom is transverse aortic constriction. Rectangles are topologically 
associated domain boundaries, and lines are chromatin interactions detected by Hi-C (Reprinted from Rosa-Garrido et al191 with permission. 
Copyright ©2017, the American Heart Association). Online Table II shows a list of genes that undergo the phenomenon described in the figure.
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Figure 4. Chromatin architectural features. A, The functional unit of chromatin is the nucleosome, which can be decorated by a 
variety of post-translational modifications that modulate accessibility to transcription factors or chromatin modifiers. B, At the gene 
level, transcription factors or repressors (green circles) confer context-specific regulation of transcription with varying levels of sequence 
specificity. DNA methylation (purple circles) typically repress promoter activity of genes although this phenomenon is associated with 
expression when found within gene bodies. C, Chromatin looping enables formation of gene expression or silencing neighborhoods, as 
well as facilitating structural units suitable for higher order packing. D, Topologically associating domains (TADs) are regions of preferential 
chromatin interactions. E, Hi-C data reveal chromatin compartmentalization into active and inactive, or A and B compartments of the 
genome, respectively (here shown in yellow and blue; note, this is a stylistic interpretation of how A and B compartments might interact 
because chromatin capture studies do not reveal actual localization coordinates within the nucleus). F, Chromosome paint experiments 
have revealed distinct territories that contain entire chromosomes within the nucleus, allowing formation of intra- and interchromosomal 
interactions that may regulate transcription or other tasks of the nucleus.
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cell types. Sub-TAD interactions, and less abundant—yet re-
producibly detected—long-range interactions that span mul-
tiple TADs (as well as interchromosomal interactions), may be 
the scales at which cell type–specific chromatin interactions 
are observed.
Chromatin structure is dynamic during the cell cycle. The 
predominance of longer range interactions present in post-
mitotic cells is rapidly lost upon entrance into G1, followed 
by further depletion throughout S and G2, in favor of shorter 
range, local interactions. This process abruptly reverses itself, 
with a return of TADs and long-range interactions after nucle-
ar division.200 Mitotic chromosomes lack TADs and chromatin 
neighborhoods, instead exhibiting a uniform, homogenous 
pattern of hierarchical interactions.201 A similar observation 
was made for oocytes in metaphase II: an absence of TADs 
and chromatin neighborhoods in these cells persisted in the 
zygote, with long range chromatin interactions manifesting at 
the 8-cell and inner cell mass stages.202 Interestingly, physical 
segregation of alleles was seen to persist until the 8-cell stage 
as well,202 even after the formation of long range chromatin 
contacts, suggesting that chromatin structure is an emergent 
property of an allele, can vary between alleles, and thus may 
participate in allelic inheritance.
Probabilistic modeling has been used to reveal 3-dimen-
sional organizational principles from Hi-C data sets, the goal 
here being not a structure per se, but a population-based rep-
resentation of the structural features of the chromosomes as 
they associate in the nucleus.203 Using data sets from human 
lymphoblastoid cells, this approach was used to schematize 
genome structure, revealing interchromosomal surfaces of ap-
position and detecting new anatomic properties of the nucle-
us, such as the physical clustering of centromeres of different 
chromosomes and the anatomic positioning of euchromatin 
and heterochromatin pockets with respect to other nuclear 
landmarks. Unlike traditional fluorescence in situ hybridiza-
tion or chromosome painting, in such an exercise one can 
know which loci are responsible for a given anatomic feature 
and in what part of the nucleus this feature tends to occur rela-
tive to other features.
The histone code17 has become a ready-to-hand tool for 
chromatin interrogation, shaping how studies are designed 
and interpreted. However, as discussed elsewhere in this es-
say, hundreds of histone PTMs are now known to exist. Also, 
the histone code and related ideas204 lack an underpinning 
in mathematical rules, a limitation addressed by investiga-
tors who have used dry laboratory approaches to character-
ize chromatin states205 or rules of nucleosome positioning206 
that reconcile ChIP-seq and chromatin accessibility data with 
genome sequence and transcription. Apart from the accordant 
histone and chromatin-binding proteins associated with dif-
ferent flavors of chromatin, how distinct chromatin domains 
form, in a physical sense, is not completely understood. Recent 
evidence from Drosophila and human chromatin suggests that 
heterochromatin domains comprised H3K9me3-marked nu-
cleosomes, heterochromatin protein 1, and DNA can exhibit 
phase separation behavior, which may be an explanation to 
link domain-scale and molecular-scale properties of hetero-
chromatin foci which can display both liquid and stable phase 
properties,207 a phenomenon supported on a broader scale by 
contemporaneous studies.160 The way forward is to integrate 
structural studies from imaging and sequencings techniques 
with genome occupancy studies to build a new model gov-
erned by principles that incorporate all these sets of data.
Integration by the Epigenome of Genetic 
Susceptibility and Environmental Risk
Histones were originally identified as inhibitors of transcrip-
tion. This concept remains a kernel of chromatin theory: 
heterochromatin increases during differentiation and loss of 
pluripotency, and some diseases, notably cancer, have been 
found to be associated with a more euchromatic environ-
ment. Because they change concomitant with gene expression 
and phenotype, chromatin modifications are ispo facto taken 
as responsible for the unidirectional progression of cell fate 
commitment in the cardiovascular system. Another hypothesis 
cached therein is that histone PTM and other chromatin marks 
stabilize cell identity. Regarding this conclusion, here is a 
premise that should be rejected: identification of a chromatin-
modifying enzyme in the heart or vasculature whose genetic 
manipulation impairs or reverses developmental state is a 
necessary and sufficient condition to prove a role for chroma-
tin in deciding and stabilizing cell fate. Here is another such 
premise of tenuous utility: if chromatin modifications stabi-
lize cell phenotype, then reprogramming strategies that restore 
pluripotency (eg, iPS [induced pluripotent stem]) or directly 
convert one cell type to another208,209 must do so by wholesale 
reprogramming of chromatin (although these processes do, no 
doubt about it, reprogram histone post-translational modifica-
tions and DNA methylation at cardiac genes210). iPS-derived 
cells coaxed toward a cardiovascular lineage acquire regula-
tory elements (ie, histone post-translational modifications on 
regulatory elements nearby lineage appropriate genes) remi-
niscent of their endogenous counterparts,211 and yet studies 
from noncardiovascular tissues have shown that iPS-derived 
cells retain some epigenetic memories from their cells of ori-
gin, which, perhaps not surprisingly, is also the case for car-
diovascular cells derived in cell culture from developmental 
precursors (eg, DNA methylation).212 Cardiac cells exhibiting 
progenitor-like behavior isolated from adult hearts indeed 
exhibit, commensurate with transcriptome changes, DNA 
methylation changes in genes associated with the mature car-
diomyocyte lineage, vis-à-vis adult cardiomyocytes lacking 
such progenitor-like behavior.213
Cell culture studies of distinct stages of cardiac lineage 
commitment explored the changes in chromatin marks associ-
ated with this process.214,215 General features of heterochromat-
ic mark (H3K27me3) loss were observed around genes that 
were expressed (genes never expressed in the cardiac lineage, 
in contrast, retained abundant H3K27me3 through differen-
tiation and never gained activating marks like H3K4me3), 
and genes that would be expressed in subsequent stages of 
development were sometimes (although not always) enriched 
with H3K4me1 (a so-called poised enhancer mark) before 
acquisition of H3K4me3 and RNA pol II concomitant with 
expression. If one were so inclined, the following observa-
tions may be taken as evidence that chromatin becomes more 
plastic in the setting of cardiac pathology (see also Figures 5 
and 6): stimulation of neonatal rat ventricular myocytes with 
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isoproterenol leads to decreased density of chromatin as mea-
sured by histone H3 immunolabeling and super resolution 
microscopy216; pressure overload hypertrophy is associated 
with a decrease in total histone H3K9me3 and increase in to-
tal H3K4me3 (as detected by Western blotting), as well as a 
decrease in the linker histone H1 to core (measured by H4) 
ratio8; association across genetically variable mouse strains 
between select chromatin structural proteins HMGB2 and 
CTCF and cardiac phenotype and the ability of HMGB2 to 
modulate cardiomyocyte hypertrophy and chromatin acces-
sibility in cardiac myocytes217; and loss of CTCF (which in-
duces cardiac dysfunction) or pressure overload hypertrophy 
is accompanied by a global decrease in genomic interactions 
detected by Hi-C.191
Meta-analysis of heart failure GWAS (Genome-Wide 
Association Study) studies recently uncovered a novel risk al-
lele associated with mortality and located in a noncoding en-
hancer region.218 Interestingly, DNA methylation signatures at 
this locus in blood were correlated with allergic sensitization, 
potentially hinting at a gene–environment interaction leaving 
an epigenetic signature. A similar observation of epigenetic 
risk conferred in a cell type–specific manner by marks pres-
ent across different tissues was recently reported in the context 
of dilated cardiomyopathy.219 The durability of these marks 
in a temporal sense remains an open question. Unequivocal 
determination of transgenerational inheritance of chromatin 
features like DNA methylation or histone modifications (dis-
cussion of which often conflates the 2 distinct concepts of 
epigenetics and Lamarckian evolution or the inheritance of ac-
quired traits) is tricky,220 and many examples are hotly debated. 
Epigenome-wide association analyses in liver demonstrate103 
DNA methylation–dependent—and sequence variation inde-
pendent—associations with clinical traits important for cardio-
vascular disease, such as insulin level, as well as other omics 
end points, providing proof of concept for population level 
epigenomic regulation of complex disease traits through the 
actions of DNA methylation variation to control phenotype, 
presumably through effects on chromatin structure or acces-
sibility. Something ostensibly heritable through cell division 
or meiosis may masquerade as epigenetic, and may even be of 
chromatic origin, while in fact proceeding via genetic means.221
It has been increasingly recognized that epigenomic modi-
fications are influenced by various diet and lifestyle factors 
that affect cardiovascular health (reviewed in detail else-
where222). Maternal smoking, for example, is known to in-
duce widespread DNA methylation differences in newborns, 
some of which persist into the offspring’s adulthood, includ-
ing in genes known to be associated with smoking-related 
birth defects,223 although whether these effects are because 
of natal exposure remains unknown. There have been limited 
experimental studies directly testing the role of nongenetic 
Figure 5. Plasticity in epigenomic landscapes may allow 
for transcriptome reprogramming in disease. Adapting 
Waddington’s concept of, to paraphrase, the chemical 
tendencies underpinning the epigenetic landscape (The 
Strategy of the Genes, New York: The Macmillan Company; 
1957), the figure depicts how, when some of the chemical 
tendencies (A; which we now know to be the DNA, proteins, 
and RNA that establish the 3-dimensional structure of the 
epigenome, blue semicircles) are perturbed by experiment or 
environment (B), the red ball (which here represents a cell or 
cell population) can adopt different positions along the energy 
landscape, becoming sufficiently plastic to enable disease-
associated gene expression.
Figure 6. Model for epigenomic 
changes in development and disease. 
Development is accompanied by changes 
in chromatin structure and regulation 
to endow terminally differentiated cells 
with stable transcriptomes. Disease 
upsets this balance, transitioning 
select regions of the genome into more 
dynamic conformations through effects 
on chromatin structure, enhancer-
gene looping and alterations in histone 
modification, DNA methylation, and 
other factors. This model is based on 
findings reviewed in the current paper 
and adapted from Rosa-Garrido et al191 
with permission. Copyright ©2017, the 
American Heart Association.
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inheritance of cardiovascular risk in animal models (eg, DNA 
methylation–dependent target gene expression in the context 
of offspring ischemic injury224). In vitro fertilization experi-
ments in mice using gametes from obese or normal weight 
parents (note: obesity was induced by high-fat diet) and sur-
rogate, normal chow fed, mothers revealed that a propensity 
for increased body weight can be inherited by nongenetic 
means.225 Metabolic gene regulation has been shown to be a 
modifiable, and subsequently heritable feature, in that mice 
fed low-protein diets passed hepatic gene expression profiles 
transgenerationally through the paternal germ line, commen-
surate with heritable changes in DNA methylation (although 
to what extent differences in DNA methylation resulting 
from distinct paternal diets directly control gene expression 
profiles remains unknown).226 Genetic variability contributes 
to chromatin accessibility (measured via FAIRE-seq) in the 
basal state and following complex metabolic changes, such 
as those accompanying high-fat diet.227 Human studies in eth-
nically diverse populations have revealed DNA methylation 
variation associated with nicotine and alcohol dependence 
(and the codependency between these forms of addiction)228 
although no evidence of inheritance or precedence of the 
phenotypes by the epigenetic features was demonstrated. In 
addition to the obvious prognostic and diagnostic potential 
of genomic and epigenomic measurements in the clinical 
arena (the practical considerations of which are discussed in 
detail elsewhere229,230), it is noteworthy that tools for reduc-
ing epigenomic treatment to practice have begun to emerge 
(Figure 7). Modification of the CRISPR/Cas9 gene targeting 
system, involving an inactive Cas9 nuclease (so-called dCas9) 
fused to DNMT3a or Tet1 and combined with guide RNAs 
to localize the complex, can induce altered DNA methylation 
of specific loci in somatic cells in vivo commensurate with 
desired changes in gene expression231 (techniques for remod-
eling chromatin loops with designer CRISPR tools have also 
emerged232). Such approaches may enable targeting of entire 
transcriptomes, rather than individual molecules, in a gene 
therapy workflow that at once provides both specificity and 
temporal tuning.
Genomic and epigenomic technologies are providing 
high-resolution descriptions of susceptibilities and patho-
genesis of cardiovascular diseases—that is, we now have 
the ability to acquire a far greater number of data points on 
patient populations, enabling identification of new biology 
but also, in the clinical setting, better stratification.230 The 
other omics technologies (such as proteomics, lipidomics, 
and metabolomics) that are now experimentally mature can, 
when applied to chromatin, provide greater still molecular 
detail on how transcriptomes are specified and cell type–
specific behavior governed in health and disease. Effective 
utilization of this wealth of knowledge to promote human 
health will require innovative thinking: some strategies will 
involve multimarker panels (eg, DNA sequence variants 
measured along with protein or lipid levels to make diagno-
ses, such as, in hypertension) whereas other strategies will 
use the intermediate end points that emerge from the col-
lective actions of multiple classes of molecules as the read-
out for diagnoses or as target for treatment (eg, targeting 
chromatin readers or chromatin accessibility, both of which 
integrate the actions of various signaling processes, protein 
modifiers, metabolites, and RNAs acting in the context of 
genetic variation).
It occurs to us that another definition of epigenomes would 
be the molecular features that make a living creature the same 
unit tomorrow that it is today. As described in the preceding 
sections, recent studies have identified the actions of discrete 
protein components and modifiers of chromatin in cardio-
vascular health and disease, providing potential targets for 
therapy. Epigenomic investigations have described chromatin 
landscapes, providing the data necessary to discover principles 
Figure 7. Cardiac epigenetic therapies. Changes in chromatin 
structure during cardiovascular pathologies alter gene expression 
and thereby phenotype. Epigenetic therapies (examples include 
histone deacetylases inhibition, BET (bromodomain and extra-
terminal) inhibition, chromatin structural protein modulation, and 
chromatin loop or DNA methylation targeting by CRISPR/Cas9 
tools) could be designed to reverse these changes by targeting 
intermediate chromatin features, such as accessibility and structure.
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for the actions of the protein and RNA modifiers. These epig-
enomic investigations also enable discovery of intermediate 
properties, like chromatin accessibility and structure, which 
may be traits that contribute to higher level phenotypes. As 
the integrator of genetics and environment, and the substrate 
of cellular memory, chromatin features may provide the ba-
sis for understanding normal and pathological cardiovascular 
function.
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